HealthEquity financials
$87.25−1.35%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Jan 31 | FY25 Jan 31 | FY24 Jan 31 | FY23 Jan 31 | FY22 Jan 31 | FY21 Jan 31 | FY20 Jan 31 | FY19 Jan 31 | FY18 Jan 31 | FY17 Jan 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.31B | $1.20B | $999.6M | $861.7M | $756.6M | $733.6M | $532.0M | $287.2M | $229.5M | $178.4M |
| Gross profit | $913.1M | $777.3M | $622.6M | $491.9M | $424.8M | $415.3M | $325.9M | $181.2M | $134.9M | $106.4M |
| Gross margin | 69.5% | 64.8% | 62.3% | 57.1% | 56.1% | 56.6% | 61.3% | 63.1% | 58.8% | 59.6% |
| Operating income | $322.5M | $162.3M | $117.7M | $9.1M | -$24.2M | $34.0M | $77.0M | $77.7M | $54.4M | $41.2M |
| Net income | $215.2M | $96.7M | $55.7M | -$26.1M | -$44.3M | $8.8M | $39.7M | $73.9M | $47.4M | $26.4M |
| Net margin | 16.4% | 8.1% | 5.6% | −3.0% | −5.9% | 1.2% | 7.5% | 25.7% | 20.6% | 14.8% |
| Diluted EPS | $2.46 | $1.09 | $0.64 | $-0.31 | $-0.53 | $0.12 | $0.58 | $1.17 | $0.77 | $0.44 |
| EBITDA | $482.1M | $365.3M | $281.2M | $198.9M | $177.8M | $195.9M | $164.5M | $95.9M | $70.4M | $54.4M |
| Operating cash flow | $457.1M | $339.9M | $242.8M | $150.7M | $143.1M | $181.6M | $105.0M | $113.4M | $81.7M | $62.2M |
| Free cash flow | $408.6M | $286.6M | $200.0M | $102.1M | $71.5M | $117.0M | $72.1M | $99.6M | $65.9M | $49.5M |
| Diluted shares | 87.5M | 88.8M | 87.0M | 84.4M | 83.1M | 75.7M | 68.5M | 63.4M | 61.9M | 59.9M |
Balance sheet
| Period end | Jan 31 | Jan 31 | Jan 31 | Jan 31 | Jan 31 | Jan 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $318.9M | $295.9M | $404.0M | $254.3M | $225.4M | $328.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $957.4M | $1.06B | $875.0M | $925.3M | $930.8M | $986.7M |
| Total assets | $3.38B | $3.45B | $3.16B | $3.09B | $3.11B | $2.71B |
| Total liabilities | $1.27B | $1.33B | $1.13B | $1.19B | $1.25B | $1.33B |
| Shareholders' equity | $2.11B | $2.11B | $2.04B | $1.90B | $1.85B | $1.38B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology